Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications.
Gaede
Peter Haulund
PH
Amtssygehuset Roskilde, Kardiologisk Afdeling, Gentofte, Denmark. peter.gaede@dadlnet.dk
D000419:Albuminuria / Q000209:etiology*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy* / Q000652:urine*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control* / Q000652:urine; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000453:epidemiology; D004032:Diet; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000453:epidemiology; D004730:Endothelium, Vascular / Q000503:physiopathology; D005919:Glomerular Filtration Rate; D015438:Health Behavior; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D007333:Insulin Resistance; D007668:Kidney / Q000503:physiopathology; D008019:Life Style; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D016540:Smoking Cessation; D016019:Survival Analysis; D016896:Treatment Outcome; D014815:Vitamins / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D010446:Peptide Fragments; D014815:Vitamins; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain